Monopar Therapeutics Inc
MNPR
Get informed when a big investor buys or sells
+ FollowMarket Cap$435.71M
Close$
$8.32
86.3% downside
Current Fair Value
86.3% downsideOvervalued by 86.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $435.71 Million |
|---|---|
| Enterprise Value | $-51,976,991,138.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.85 |
| Beta | 1.5 |
| Outstanding Shares | 8,535,000 |
Return
| Return on Equity | -2.55% |
|---|---|
| Return on Assets | -2.50% |
| Return on Invested Capital | -3.03% |
Valuation & Multiples
| P/E Ratio | -37.04 |
|---|---|
| PEG | 37.1 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 12.66 |
| Enterprise Value to Net Income | 15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-1.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 93.17%▲ 15.65% |
|---|---|
| Total Invested | $341.52M▼ 5.27% |
| Investors Holding | 81▲ 9.00% |
ESG Score
No data
About Monopar Therapeutics Inc
10 employeesMonopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validi...